Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, multinational, non-randomized, non-controlled open-label phase II
trial to evaluate the safety and efficacy of treosulfan in a combination regimen with
fludarabine as conditioning therapy prior to allogeneic stem cell transplantation (SCT) in
patients with AML.
The aim is to demonstrate a clinical benefit compared with historical data on intravenous
busulfan (BusulfexTM, BusilvexTM), the only drug so far registered in the indication
conditioning before allogeneic stem cell transplantation.